Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.12.21	Novartis: New Data Shows Efficacy Of Piqray In HR+/HER2- Metastatic Breast Cancer (RTTNews)
10.12.21	Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i (PR Newswire)
09.12.21	Dr. Reddy's Labs Unveils Valsartan Tablets, USP In U.S. (RTTNews)
08.12.21	New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer (GlobeNewswire)
03.12.21	Sandoz Recalls One Lot Of Enoxaparin Sodium Injection (RTTNews)
02.12.21	UCB Signs Up To $1.5 Bln Deal With Novartis To Co-develop Two Parkinson's Disease Drugs (RTTNews)
04.11.21	Novartis To Sell 53.3 Mln Roche Shares To Roche For $20.7 Bln (RTTNews)
01.11.21	Novartis' Scemblix Gets FDA Approval To Treat Chronic Myeloid Leukemia (RTTNews)
26.10.21	Novartis Q3 Profit Tops View, Sales Match; Backs FY21 View; Mulls Strategic Options For Sandoz (RTTNews)
30.09.21	Novartis Commits To Achieving Net Zero Carbon Emissions Across Value Chain By 2040 (RTTNews)
19.09.21	Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer (PR Newswire)
17.09.21	NVS: Study On Alpelisib Shows Clinical Benefit In People With PIK3CA-Related Overgrowth Spectrum (RTTNews)
17.09.21	Novartis Reports Positive Data For Radioligand Therapy In Patients With Advanced Prostate Cancer (RTTNews)
13.09.21	BeiGene : FDA Accepts BLA For Tislelizumab In Esophageal Squamous Cell Carcinoma (RTTNews)
08.09.21	Sandoz, Bio-Thera Reach Deal On Biosimilar Bevacizumab For Treatment Of Multiple Types Of Cancers (RTTNews)
01.09.21	Novartis Reaches Agreement With U.K's NHS For Cholesterol Drug Leqvio (RTTNews)
24.08.21	Novartis Says Phase III Kymriah Trial In Aggressive B-cell NHL Did Not Meet Primary Goal (RTTNews)
12.08.21	Cipla Gets FDA Nod For Generic Equivalent Of Novartis' Durezol - Quick Facts (RTTNews)
03.08.21	Novartis : FDA Lifts Partial Clinical Trial Hold On Spinal Muscular Atrophy Study (RTTNews)
02.08.21	Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events (PR Newswire)
21.07.21	Novartis Q2 Results Climb, Top Estimates; Maintains FY21 Outlook - Quick Facts (RTTNews)
28.06.21	Novartis Names Rob Kowalski Chief People & Organization Officer (RTTNews)
07.06.21	Novartis' Iptacopan Meets Primary Endpoint In Phase II Study On Rare Kidney Disease (RTTNews)
04.06.21	Novartis Says Tislelizumab Met Primary Endpoint Of OS In Pivotal Phase III Trial - Quick Facts (RTTNews)
02.06.21	Novartis Announces Higher OS Results For Kisqali + Fulvestrant In Extended Follow-up - Quick Facts (RTTNews)
02.06.21	Novartis : Late-stage Study On Cosentyx Meets Primary Endpoint In Juvenile Idiopathic Arthritis (RTTNews)
02.06.21	FDA Approves Novartis' Cosentyx To Treat Plaque Psoriasis In Pediatric Patients (RTTNews)
27.05.21	Novartis, Molecular Partners To Start Phase II & III Trials Of COVID-19 Treatment (RTTNews)
17.05.21	Sandoz Says US Supreme Court Denies Its Petition To Review Biosimilar Erelzi Case (RTTNews)
03.05.21	Sandoz To Begin Enrolling First Patient In MYLIGHT Study For Proposed Biosimilar Aflibercept (RTTNews)
01.05.21	Novartis : Phase III Beovu Data Show Potential For Fluid Resolution In More DME Patients (RTTNews)
27.04.21	Novartis Q1 Results Miss View - Quick Facts (RTTNews)
13.04.21	FDA Approves Roche's Xolair Prefilled Syringe For Self-Injection Across All Indications (RTTNews)
07.04.21	Novartis Collaborates With Artios To Use Three DDR Targets With Radioligand Therapies (RTTNews)
30.03.21	Genmab: Novartis Gets European Approval For Kesimpta To Treat Relapsing Multiple Sclerosis In Adults (RTTNews)
30.03.21	Novartis Gets Rights To Develop Therapeutic Applications For Library Of FAP Assets (RTTNews)
23.03.21	Novartis: Phase III VISION Study With Radioligand Therapy 177Lu-PSMA-617 Met Both Primary Endpoints (RTTNews)
22.03.21	Novartis Picks Karen Hale As New Chief Legal Officer, Effective May 15- Quick Facts (RTTNews)
17.03.21	CELC Inks Breast Cancer Trial Collaboration, CANF Soars On Deal With Ewopharma, MRUS On Watch (RTTNews)
15.03.21	Novartis: Zolgensma Shows Sustained Durability In Children With SMA Now Up To Six Years Old (RTTNews)
09.03.21	Novartis: Phase III CANOPY-2 Trial Of Canakinumab Fails To Meet Primary Endpoint (RTTNews)
05.03.21	Novartis Chief Legal Officer Shannon Klinger To Step Down, Names Thomas Kendris CLO Ad Interim (RTTNews)
04.03.21	CureVac, Novartis Sign Initial Agreement For Manufacturing Of CureVac's COVID-19 Vaccine Candidate (RTTNews)
02.03.21	Novartis Shareholders Approve All Resolutions Proposed By Board (RTTNews)
17.02.21	Novartis, Bill & Melinda Gates Foundation Collaborate On Vivo Gene Therapy For Sickle Cell Disease (RTTNews)
17.02.21	BLUE Hit By SCD Trial Blues, CRTX Plunges On Partial Hold, SESN To Face FDA In August (RTTNews)
11.02.21	Novartis' Sandoz To Buy GSK's Cephalosporin Antibiotics Business - Quick Facts (RTTNews)
26.01.21	Novartis Q4 Profit Rises, But Results Miss View (RTTNews)
12.01.21	BGNE Teams Up With NVS, Editas Slumps Over 15%, LLY's Drug Shines In TRAILBLAZER-ALZ, MESO On Watch (RTTNews)
12.01.21	BeiGene Collaborates With Novartis To Develop Cancer Drug; To Receive Up To $1.55 Bln Payments (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.14	1.54 %	K V
UBS Group	28.08	1.48 %	K V
Swiss Re	130.05	1.05 %	K V
Part Grp Hldg	1’266.00	0.96 %	K V
ABB	49.48	0.94 %	K V
Geberit	525.20	0.27 %	K V
Alcon	78.04	0.05 %	K V
Givaudan	3’868.00	-0.31 %	K V
CieFinRichemont	121.20	-0.57 %	K V
Sonova Hldg	301.00	-0.99 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert